Cellectar Biosciences Inc... (CLRB)
0.28
-0.01 (-3.28%)
At close: Mar 03, 2025, 3:57 PM
0.28
-0.83%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 0.25 |
| Market Cap | 12.83M |
| Revenue (ttm) | 387.01K |
| Net Income (ttm) | -52.26M |
| EPS (ttm) | -1.41 |
| PE Ratio (ttm) | -0.2 |
| Forward PE | -0.38 |
| Analyst | Buy |
| Ask | 0.3 |
| Volume | 681,091 |
| Avg. Volume (20D) | 2,903,906 |
| Open | 0.30 |
| Previous Close | 0.29 |
| Day's Range | 0.27 - 0.30 |
| 52-Week Range | 0.22 - 4.45 |
| Beta | 1.05 |
About CLRB
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients;...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2005
Employees 20
Stock Exchange NASDAQ
Ticker Symbol CLRB
Website https://www.cellectar.com
Analyst Forecast
According to 2 analyst ratings, the average rating for CLRB stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 9953.86% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
2 months ago
-76.16%
Cellectar Biosciences shares are trading lower aft...
Unlock content with
Pro Subscription
7 months ago
-18.54%
Cellectar Biosciences shares are trading lower. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.
